Evidence map›Paper›PMID 30302739›Full record

ArticleInternational journal of hematology2019

Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults.

Yasuko Yamagishi, Takaaki Konuma, Yoriko Miwa, Maki Oiwa-Monna, Susumu Tanoue, Masamichi Isobe, Koji Jimbo, Mai Mizusawa, Hatsuko Narita, Koji Kobayashi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuko YamagishiDepartment of Nursing, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takaaki KonumaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. tkonuma@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-1953-8463
Yoriko MiwaDepartment of Nursing, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Maki Oiwa-MonnaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Susumu TanoueDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Masamichi IsobeDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Koji JimboDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Mai MizusawaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Hatsuko NaritaDepartment of Nursing, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koji KobayashiDepartment of Nursing, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seiko KatoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Satoshi TakahashiDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Arinobu TojoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hospital readmissions have been used as a prognostic indicator for patients receiving allogeneic hematopoietic cell transplantation (HCT). However, the impact of readmission during early and mid-phase of cord blood transplantation (CBT) on long-term outcomes has not been fully investigated. We retrospectively analyzed 156 adult patients who received single-unit CBT in our institute. Among this cohort, thirteen patients (8%) were readmitted within 30 days after discharge, and 27 (17%) were readmitted within 90 days after discharge. The most common causes for readmission within 30 and 90 days of discharge were infection, chronic graft-versus-host disease, and relapse. Higher cryopreserved cord blood CD34

Indexed as

Patient ReadmissionAdultCord Blood Stem Cell TransplantationFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansInfectionsMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesRisk FactorsSurvival AnalysisTime FactorsCord blood transplantationDischargeInfectionLength of hospital stayReadmission

Identifiers

PMID30302739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.